Neurofilament Light Aptamer Sensors for Early Fluid Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current biomarker tests for diagnosing dementia, such as Alzheimer's disease, are invasive, expensive, and only performed after cognitive impairment has been detected, limiting intervention options and effectiveness.
Innovation Solution
Development of aptamer molecules that selectively bind to neurofilament light (NFL) for use in biosensors, allowing for non-invasive, cost-effective detection in body fluids like saliva, urine, and blood, using electrochemical, optical, or electrical methods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If antibodies are used for biomarker detection, then binding affinity and selectivity are achieved, but the method becomes expensive, invasive, and requires long testing times
Solution Approach 1:
The patent replaces expensive, fragile antibodies with inexpensive, stable aptamers that can be synthesized chemically. Aptamers are single-stranded DNA or RNA molecules that bind to target biomarkers with high affinity but cost far less to produce and do not require complex animal testing or purification processes, thereby reducing both cost and testing time while maintaining detection accuracy
Solution Approach 2:
The patent substitutes the biological antibody-based ELISA method with an electrochemical detection system using aptamers. This replacement eliminates the need for enzymatic reactions and optical reading equipment, enabling rapid, instrument-free detection that significantly reduces testing time and increases productivity
2Loss of time
If PET scans are used for biomarker detection, then early disease detection is possible, but the method becomes very expensive and invasive
Solution Approach 1:
The patent employs inexpensive aptamer-based sensors that can be manufactured at low cost and used for routine screening. These sensors enable early detection through simple, non-invasive sampling (e.g., blood or urine collection) rather than expensive PET scans, making early detection accessible for population screening without the harmful invasiveness of radioactive tracers
Solution Approach 2:
The patent uses aptamers as intermediary molecules that bind to neurofilament light chains in body fluids as early indicators of neurodegeneration. This intermediary approach allows detection of molecular changes before clinical symptoms appear, enabling early intervention without requiring invasive imaging procedures
3Measurement precision
If ELISA tests are used for biomarker determination, then diagnostic accuracy is achieved, but the method becomes expensive and requires experienced personnel
Solution Approach 1:
The patent replaces the complex, multi-step ELISA procedure with a simplified electrochemical aptamer assay. The aptamer binds to the target biomarker, and the binding event is detected directly through electrochemical signals, eliminating the need for enzyme conjugation, multiple washing steps, and specialized plate readers. This simplification maintains diagnostic accuracy while making the test easy to perform with minimal training
Solution Approach 2:
The patent designs the aptamer sensor system to provide self-contained detection functionality. The aptamer is immobilized on an electrode surface and automatically binds to target molecules in the sample, generating a measurable electrochemical signal without requiring manual intervention for enzyme addition, substrate incubation, or signal development steps that characterize traditional ELISA
4Reliability
If antibodies are used for biomarker detection, then high binding affinity is achieved, but the antibodies become sensitive to degradation and require animal testing
Solution Approach 1:
The patent replaces protein-based antibodies with nucleic acid-based aptamers that are chemically synthesized rather than biologically produced. This substitution eliminates sensitivity to proteolytic degradation and batch-to-batch variability inherent in antibody production, while also eliminating the need for animal testing. Aptamers exhibit superior stability under various storage and experimental conditions
Solution Approach 2:
The patent changes the fundamental chemical nature of the binding molecule from protein (antibody) to nucleic acid (aptamer). This parameter change confers enhanced stability against degradation, as nucleic acids are more resistant to enzymatic breakdown and maintain structural integrity across a broader range of temperatures and pH conditions, thereby improving reliability without requiring cold chain storage
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables early detection of NFL in body fluids, providing a higher probability of successful intervention by being minimally invasive, cost-effective, and suitable for point-of-care testing.
Implementation Method 1
aptamer molecules that bind selectively and with high affinity to neurofilament light
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to aptamers that bind to neurofilament light, biosensors, uses of the aptamers, and methods for detecting neurofilament light.